BMEA - Why Biomea Fusion (BMEA) Stock Is Down 60% | Benzinga

Biomea Fusion Inc (NASDAQ:BMEA) shares are trading lower by 62.7% to $4.20 during Friday’s session after the company received notice from the FDA that Its trials of BMF-219 have been placed on clinical hold. The stock also received a number of analyst rating revisions following the business update.

The hold was due to concerns about possible drug-induced hepatotoxicity observed during the Dose Escalation Phase of COVALENT-111, though no serious adverse reactions have been reported.

Despite the hold, Biomea will continue collecting safety and efficacy data and is working with the FDA to address these concerns. CEO Thomas Butler emphasized the company’s commitment to patient safety and the potential ...

BMEA) Stock Is Down 60%>Full story available on Benzinga.com